WO2010013769A1 - チアゾリジンジオン化合物の結晶及びその製造方法 - Google Patents

チアゾリジンジオン化合物の結晶及びその製造方法 Download PDF

Info

Publication number
WO2010013769A1
WO2010013769A1 PCT/JP2009/063558 JP2009063558W WO2010013769A1 WO 2010013769 A1 WO2010013769 A1 WO 2010013769A1 JP 2009063558 W JP2009063558 W JP 2009063558W WO 2010013769 A1 WO2010013769 A1 WO 2010013769A1
Authority
WO
WIPO (PCT)
Prior art keywords
crystal
production
compound
thiazolidinedione compound
disclosed
Prior art date
Application number
PCT/JP2009/063558
Other languages
English (en)
French (fr)
Inventor
久喜 梶野
英治 沼上
悟 二瓶
Original Assignee
第一三共株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 第一三共株式会社 filed Critical 第一三共株式会社
Priority to EP09803011A priority Critical patent/EP2311834A4/en
Priority to JP2010522749A priority patent/JPWO2010013769A1/ja
Priority to US13/056,649 priority patent/US20110160462A1/en
Publication of WO2010013769A1 publication Critical patent/WO2010013769A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B63/00—Purification; Separation; Stabilisation; Use of additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

ペルオキシソーム増殖因子活性化受容体（ＰＰＡＲ）γ活性化剤、抗癌医薬組成物の製造原体として有用な、チアゾリジンジオン化合物の結晶を提供する。　 下記一般式（I）： で表される、５－(４－{[６－(４－アミノ－３,５－ジメチルフェノキシ)－１－メチル－１－Ｈ－ベンツイミダゾール－２－イル]メトキシ}ベンジル)－１,３－チアゾリジン－２,４－ジオン、およびその２塩酸塩の水和物結晶。
PCT/JP2009/063558 2008-07-31 2009-07-30 チアゾリジンジオン化合物の結晶及びその製造方法 WO2010013769A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP09803011A EP2311834A4 (en) 2008-07-31 2009-07-30 CRYSTAL OF A THIAZOLIDINE CONNECTION AND METHOD FOR THE PRODUCTION THEREOF
JP2010522749A JPWO2010013769A1 (ja) 2008-07-31 2009-07-30 チアゾリジンジオン化合物の結晶及びその製造方法
US13/056,649 US20110160462A1 (en) 2008-07-31 2009-07-30 Crystalline forms of thiazolidinedione compound and its manufacturing method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008197307 2008-07-31
JP2008-197307 2008-07-31

Publications (1)

Publication Number Publication Date
WO2010013769A1 true WO2010013769A1 (ja) 2010-02-04

Family

ID=41610468

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2009/063558 WO2010013769A1 (ja) 2008-07-31 2009-07-30 チアゾリジンジオン化合物の結晶及びその製造方法

Country Status (5)

Country Link
US (1) US20110160462A1 (ja)
EP (1) EP2311834A4 (ja)
JP (1) JPWO2010013769A1 (ja)
TW (1) TW201008936A (ja)
WO (1) WO2010013769A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201336497A (zh) 2007-02-08 2013-09-16 Daiichi Sankyo Co Ltd 噻唑啶二酮化合物之結晶型及其製法

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999018081A1 (fr) 1997-10-08 1999-04-15 Sankyo Company, Limited Composes heterocycliques condenses substitues
JPH11193276A (ja) * 1997-10-08 1999-07-21 Sankyo Co Ltd 置換縮合複素環化合物
JP2000351769A (ja) * 1999-04-07 2000-12-19 Sankyo Co Ltd インスリン抵抗性改善剤
JP2000351779A (ja) * 1999-04-07 2000-12-19 Sankyo Co Ltd アミン誘導体化合物
JP2002179568A (ja) * 2000-10-06 2002-06-26 Sankyo Co Ltd アミン誘導体化合物を含有する糖尿病予防剤、治療剤
WO2003053440A1 (fr) 2001-12-11 2003-07-03 Sankyo Company, Limited Composition medicinale
JP2003238406A (ja) 2001-12-11 2003-08-27 Sankyo Co Ltd 医薬組成物
WO2004000356A1 (ja) 2002-06-25 2003-12-31 Sankyo Company, Limited 利尿剤及びペルオキシソーム増殖因子活性化受容体（PPAR)γ活性化剤を含有する医薬組成物
JP2004083574A (ja) 2002-06-25 2004-03-18 Sankyo Co Ltd 利尿剤及びペルオキシソーム増殖因子活性化受容体（ＰＰＡＲ）γ活性化剤を含有する医薬組成物
WO2004083167A1 (ja) 2003-03-18 2004-09-30 Sankyo Company Limited スルファミド誘導体及びその医薬組成物
JP2005162727A (ja) 2003-03-18 2005-06-23 Sankyo Co Ltd スルファミド誘導体及びその医薬組成物
WO2007091622A1 (ja) 2006-02-09 2007-08-16 Daiichi Sankyo Company, Limited 抗癌医薬組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE466861T1 (de) * 1999-04-07 2010-05-15 Daiichi Sankyo Co Ltd Aminderivate
TW201336497A (zh) * 2007-02-08 2013-09-16 Daiichi Sankyo Co Ltd 噻唑啶二酮化合物之結晶型及其製法
TW201008935A (en) * 2008-07-31 2010-03-01 Daiichi Sankyo Co Ltd Crystalline forms of thiazolidinedione compound and its manufacturing method

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432993B1 (en) 1997-10-08 2002-08-13 Sankyo Company, Limited Substituted fused heterocyclic compound
JPH11193276A (ja) * 1997-10-08 1999-07-21 Sankyo Co Ltd 置換縮合複素環化合物
EP1022272A1 (en) 1997-10-08 2000-07-26 Sankyo Company Limited Substituted fused heterocyclic compounds
WO1999018081A1 (fr) 1997-10-08 1999-04-15 Sankyo Company, Limited Composes heterocycliques condenses substitues
JP3488099B2 (ja) 1997-10-08 2004-01-19 三共株式会社 置換縮合複素環化合物
JP2000351769A (ja) * 1999-04-07 2000-12-19 Sankyo Co Ltd インスリン抵抗性改善剤
JP2000351779A (ja) * 1999-04-07 2000-12-19 Sankyo Co Ltd アミン誘導体化合物
JP2002179568A (ja) * 2000-10-06 2002-06-26 Sankyo Co Ltd アミン誘導体化合物を含有する糖尿病予防剤、治療剤
WO2003053440A1 (fr) 2001-12-11 2003-07-03 Sankyo Company, Limited Composition medicinale
JP2003238406A (ja) 2001-12-11 2003-08-27 Sankyo Co Ltd 医薬組成物
WO2004000356A1 (ja) 2002-06-25 2003-12-31 Sankyo Company, Limited 利尿剤及びペルオキシソーム増殖因子活性化受容体（PPAR)γ活性化剤を含有する医薬組成物
JP2004083574A (ja) 2002-06-25 2004-03-18 Sankyo Co Ltd 利尿剤及びペルオキシソーム増殖因子活性化受容体（ＰＰＡＲ）γ活性化剤を含有する医薬組成物
WO2004083167A1 (ja) 2003-03-18 2004-09-30 Sankyo Company Limited スルファミド誘導体及びその医薬組成物
JP2005162727A (ja) 2003-03-18 2005-06-23 Sankyo Co Ltd スルファミド誘導体及びその医薬組成物
WO2007091622A1 (ja) 2006-02-09 2007-08-16 Daiichi Sankyo Company, Limited 抗癌医薬組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2311834A4 *

Also Published As

Publication number Publication date
US20110160462A1 (en) 2011-06-30
TW201008936A (en) 2010-03-01
JPWO2010013769A1 (ja) 2012-01-12
EP2311834A4 (en) 2011-11-02
EP2311834A1 (en) 2011-04-20

Similar Documents

Publication Publication Date Title
MX2009003535A (es) Formas cristalinas de un compuesto de tiazolidinodiona, y metodos de fabricacion de las mismas.
NZ600801A (en) Substituted imidazopyridinyl-aminopyridine compounds
NO20083514L (no) Heterobicykliske sulfonamidderivater for behandling av diabetes
NZ592297A (en) 2-Aryl-5-heteroaryl pyridine and pyrimidine derivatives as pharmaceutical active agents
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
WO2009068170A3 (de) 2- (benzyl- und 1h- pyrazol-4 -ylmethyl) sulfinyl-thiazol-derivate als herbizide und pflanzenwachstumsregulatoren
NO20085066L (no) 4,5-difenyl-pyrimidinyl-aminosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
NO20092314L (no) Benzamidderivater som EP4 receptoragonister
WO2009010416A3 (en) Inhibitors of 11b-hydroxysteroid dehydrogenase
NO20085121L (no) Benzimidazolderivater, deres fremstillingsmate, deres anvendelse som FXR-agonister og farmasoytiske blandinger inneholdende samme
NO20084403L (no) Cykloheksylpyrazol-lactamderivater som inhibitorer av II-beta-hydroksysteroid dehydrogenase I
WO2007125405A3 (en) Substituted 2-amino-fused heterocyclic compounds
WO2010036613A8 (en) Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2008046758A3 (en) Imidazolone and imidazolidinone derivatives as 11b-hsd1 inhibitors for diabetes
CL2008002142A1 (es) Compuestos derivados de 2-amino-6-({[2-(4-clorofenil)-1,3-tiazol-4-il]metil}tio)-4-[4-(2-hidroxietoxi) fenil] piridin-3,5-dicarbonitrilo; procedimiento de preparacion; composicion farmaceutica y uso en enfermedades cardiovasculares.
NO20085064L (no) 4,5-difenyl-pyrimidinyl-oksy eller -merkaptosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
WO2008126899A1 (ja) ５員環へテロ環誘導体及びその医薬用途
WO2007106879A3 (en) Process for preparing n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide and related metabolites thereof
SG10201407430TA (en) N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
MY163114A (en) Cyclopentylacrylamide derivative
NZ587518A (en) Crystalline form III of (3,5-bis trifluoromethyl)-N-[4-methyl-3-({ 4-(pyridin-3 yl)-pyrimidin-2-yl} amino)-phenyl]-benzamide
WO2009080705A3 (en) Bis-thiazole derivatives, process for their preparation and their use as medicaments
WO2008126732A1 (ja) 縮合二環式ヘテロアリール誘導体
NO20090282L (no) Syklopropylaminderivater som histamin H3 reseptormodulatorer
HK1146049A1 (en) Isoxazole derivatives as modulators of 11-beta-hydroxysteroid dehydrogenase type 1

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09803011

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2010522749

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2009803011

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE